ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Ticker Update

Updates

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on SmofKabiven extra Nitrogen Electrolyte Free

Fresenius Kabi Ltd & Calea UK Ltd has informed us of an error on the bag labels for SmofKabiven extra nitrogen electrolyte free, emulsion for infusion PL 08828/0269. A sentence has been inadvertently included stating "with electrolytes" on an electrolyte free product. The outer cartons and leaflets have been checked and these are all in compliance. The bag label should state "1. Amino acid solution.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
Alliance do not stockSmofKabiven extra Nitrogen Electrolyte FreeFresenius Kabi Ltd & Calea UK Ltd10NI3300
10PB8836

Alliance healthcare do not stock this product and as this is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact: Medical.Information-UK@fresenius-kabi.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

 

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Phosphates Solution For Infusion 500ml

Huddersfield Pharmacy Specials (HPS) is recalling the above batches of phosphates solution for infusion due to observation of precipitation in batch 500609X. The decision to recall all other batches has been made as a precautionary measure.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
Alliance do not stockPhosphates Solution For Infusion 500mlHuddersfield Pharmacy Specials (HPS)Please follow the above link

Alliance Healthcare do not stock this line therefore we will not be accepting customer returns.

For stock control queries please contact: HPS Customer Services, 01484 355388.

For any medical information enquires please contact: Dr Burrinder Grewal, 01484 355230.

 

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CORPORATE NEWS

Julian Mount, Managing Director takes part in Covid-19 roundtable discussion with Pharmacy Business

Julian Mount, Managing Director at Alliance Healthcare in the UK, Sutton contractor Reena Barai, and chief executive of PCT Healthcare Peter Cattee took in the second Pharmacy Business virtual roundtable.

 

The coronavirus pandemic will lead community pharmacy into becoming the healthcare hub of the future, a leading pharmaceutical professional has said.

 

Managing Director of Alliance Healthcare UK Julian Mount believes in a post-Covid world more remote interactions from doctors and hospitals will be the order of the day, making community pharmacy the first in line for face-to-face healthcare advice.

 

Julian Mount shares his view on the challenges community pharmacy has faced during the Covid-19 pandemic

 

"If there is a positive experience with Covid-19, it's the positivity there is now around having that healthcare hub within the community," he said at Pharmacy Business' second virtual roundtable entitled ‘Reimagining community pharmacy in a post-Covid world'.

 

The roundtable delved into the future of pharmacy from the perspectives of a pharmacy wholesaler, an independent contractor and an owner of a chain of community pharmacies. It explored how a hugely positive public perception, renewed national recognition and changed attitude from the powers that be could reinvigorate community pharmacy as well as how the sector needed to adapt in the rapidly changing world of technology.

 

The three-member panel, which also included chief executive of PCT Healthcare Peter Cattee and Sutton contractor Reena Barai, felt that community pharmacy should build on the positivity it now has but the onus of continuing that momentum would be on the national pharmacy bodies.

 

WATCH THE VIDEO or READ THE FULL ARTICLE

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Clexane 4,000 Iu (40mg) /0.4ml Syringes

Pharmaram Ltd has informed us that the below batch of Clexane 4,000IU (40mg)/0.4ml syringes has an error on the labelling affixed to the plastic blister packaging encasing the syringe. The label incorrectly states "Clexane 6,000IU (60mg)/0.6ml Syringes", when it should have stated "Clexane 4,000IU (40mg)/0.4ml Syringes". The outer carton states the correct strength; the batch number and expiry dates are also correct and match the details on the labelling.

 

Please visit the: MHRA website for more details on this drug alert.

 

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
8129165PI CLEXANE PFS 40MGPHARMARAM LTDCCL67G/D3

For stock control queries please contact:Pharmaram Ltd Austin Chambers Email: austin@dixpharm.com Tel: +44 (0) 1530 410920 Mob: +44 (0) 7944 664400

For any medical information enquires please contact: Pharmaram Ltd Email: quality@dixpharm.com Tel: +44 (0) 1530 410920

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in Use on SyreniRing 0.120 mg/0.015 mg per 24 hours, vaginal delivery system

Crescent Pharma Ltd has informed us that the Patient Information Leaflet (PIL) within the packs for the below batches is missing important safety relevant text changes.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch

4091625SYRENIRING 0.12MG/0.015MG 24 HRCRESCENT PHARMA LTDLF18276AA
LF18894AA

This may have been supplied by AHDL. Unfortunately we are not providing specific batch information you will be required to follow the instructions as per the drug alert.

This is a caution in use only we are not accepting stock returns.


For more information or medical information queries, please contact: Crescent Pharma Ltd. Medical Information Department on +00351 214643225, via email on tiago.barca@pharsolution.com or +44 (0) 1256 772740.

 

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

 

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 3 RECALL

Class 3 Recall on Digoxin Tab 250mcg

Accord-UK Ltd has informed us of an issue related to decommissioning of the above batch. Upon decommissioning at the pharmacy, there have been reports stating that when scanning the serialised 2D code, the status of packs may report as ‘EXPORT.' Although there is no risk to product quality, any remaining stock should be quarantined and returned.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionLiveryAffected Batch
1063015Digoxin Tab 250mcgAccord UK LtdXDG396

For stock control enquiries please contact Accord-UK Ltd Customer Services Team on 0800 373573.

For medical information enquiries please contact Accord-UK Ltd Medical Information Department on 01271 385257.

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

Class 2 Recall on Abstral Tab 200mcg (Schedule 2 CD)

Kyowa Kirin Limited is recalling the above batch as a precautionary measure, due to the reports of double tablets in a single blister pocket. This was identified during reference sample inspection and there is a potential low risk of accidental double dosage.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionSupplierAffected Batch
3460375ABSTRAL TAB 200MCG (SCHEDULE 2 CD)KYOWA KIRIN608777302

As this product is a Schedule 2 Controlled Drug. Please ensure that these returns are sent back with the Alliance Healthcare driver, who will have a ‘Specialist Product Recall Book' with them on Thursday 30th and Friday 31st July for completion and product uplift AM ONLY. If you have recalled products to return, please have this prepared in a bag for the driver to uplift. Due to Covid 19, the driver will complete the form on your behalf. They will ask for the quantity of stock you have to return and the name of the pharmacist. The driver will give you a copy of the completed form for your records. Please use our Returns Portal from Saturday 1st August for any additional returns related to this recall or alternatively call Customer Service for authorisation to return

Further Information

For Stock control enquiries please contact: Stuart Hay, Commercial Director Telephone: +44 (0) 1896 664045 Mobile: +44 (0) 7968 983286 E-mail: Stuart.Hay@kyowakirin.com For Medical information enquiries please contact:

Medical Information Direct Line: + 44 (0)1896 664 000 E-mail: medinfo@kyowakirin.com For Quality information please contact: Martin Smith (Responsible Person)

Telephone: +44 7904671807 E-mail: Martin.Smith@kyowakirin.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CSR ACHIEVEMENTS

Alliance Healthcare Reduces its Use of Single-Use Plastic Bags and Cardboard Boxes

Alliance Healthcare has started to roll out new reusable tote bins to replace plastic bags and cardboard packaging to its Health and Beauty customers.

 

Every year, over 2 million units of single-use plastic bags and cardboard boxes will be removed from its operations, considerably lessening Alliance Healthcare's carbon footprint.

 

The new reusable tote bins will be available in two sizes to consolidate customer orders and reduce the number of packages in circulation, minimising product damage and supporting Alliance Healthcare's commitment to reduce its impact on the environment.

 

Jon Cornforth, Environment, Health and Safety Manager, says: "Reducing plastic waste has globally become an important issue over the last couple of years and we have a responsibility to reduce our impact on the environment. By replacing plastic bags and cardboard packaging with our reusable totes we can reduce waste and move away from our reliance on plastic in our operations."

 

The totes are white with black lids and feature the Alliance Healthcare branding as well as a new Health and Beauty icon.

SUB-TYPE:

Alliance Healthcare site in Letchworth celebrates 30 years of delivering medicines

Employees have marked 30 years of Letchworth Service Centre, with a special birthday celebration.

 

The site was officially opened in 1990 by Kenneth Clarke, Secretary of State for Health at the time, who welcomed colleagues that had moved to the new site from Willesdon in north west London.

 

Over 430 colleagues in the local area are employed at the site and 46 have over 20 years' service.

 

Brian Smith is the longest serving employee at Letchworth and the second longest serving at Alliance Healthcare. He says: "I moved across from Willesdon to Letchworth when it first opened in 1990. I like working here, I've been well looked and I like the people. I'm proud that I've been part of the team for nearly 48 years and been able to support the NHS, particularly during Covid-19."

 

At 85,000 square feet, Letchworth is one of the biggest service centres in the Alliance Healthcare network, delivering on average 200,000 medicines on a twice daily* basis to over 3,200 pharmacies, hospitals and GP surgeries across East Anglia, north London and as far west as Oxford. At the height of the Covid-19 pandemic over 343,000 units were being despatched.

 

David Fussey, Service Centre Manager, says: "I feel immensely proud to be able to celebrate 30 years of Letchworth. I've never worked for a business where I have been able to celebrate such an important milestone. The team is very dedicated and always puts the customer first."

 

*Two deliveries every week day and one on Saturdays as agreed with the customer

 

 

SUB-TYPE: CLASS 3 RECALL

Class 3 Recall on Irinotecan Vial 20mg/Ml

Accord Healthcare Limited is recalling the above batch as a precautionary measure, due to the observation of precipitation in the solution in the same batch marketed in another country (Malta). No complaints or adverse reaction reports have been received by the company to date for the UK product.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP CodeProduct DescriptionLiveryAffected Batch
1216860Irinotecan Vial 20mg/MlAccord HealthcareX21343
1123835Irinotecan Vial 20mg/MlAccord HealthcareX21343

For more information or medical information queries, please contact:Medinfo-BST Tel: 01271 385257 E-mail: medinfo@accord-healthcare.com

For stock control queries, please contact: Accord-UK Ltd Customer Services Team Tel: 0800 373573 E-mail: customerservices@accord-healthcare.com Fax: 01271 346106

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.